Cytokinetics, Incorporated
US ˙ NasdaqGS ˙ US23282W6057

SecurityCYTK / Cytokinetics, Incorporated
InstitutionStandard Life Aberdeen plc
Latest Disclosed Ownership483,274 shares
Latest Disclosed Value $ 31,852,589
Standard Life Aberdeen plc reports 0.04% increase in ownership of CYTK / Cytokinetics, Incorporated

On April 29, 2026 - Standard Life Aberdeen plc filed a 13F-HR form disclosing ownership of 483,274 shares of Cytokinetics, Incorporated (US:CYTK) valued at $31,852,589 USD as of March 31, 2026. The entity filed a previous 13F-HR on January 16, 2026 disclosing 483,061 shares of Cytokinetics, Incorporated. This represents a change in shares of 0.04% during the quarter. The current value of the position is $34,544,426 USD.

Institutional Ownership: 13F and NPORT Filings

The Security and Class in the table below are shown exactly as filed by the investor. We do our best to track continuity of investments through acquisitions, and this will be reflected in the table as changes in names. In addition to descriptive data, performance of the investment is shown over time. To calculate quarterly performance, we first calculate cost basis of the shares purchased during the quarter, then use that to calculate gross profit. Quarterly return is Gross Profit / Starting Portfolio value.

Note that cost basis is calculated and stored in thousands, so small quarterly changes in shares frequently result in a cost basis of zero.

Upgrade to unlock premium data and export to Excel .

Disclosed Equity Positions (from 13F/NPORT Filings)
File
Date		 Effective
Date		Form Security Class ID Avg Price
Paid (Est)		 Reported
Shares		 ΔShares ΔShares
(%)		 Reported
Value
(x1000)		 ΔValue
(%)		 Alloc
(%)		 ΔAlloc ΔAlloc (%) Cost Basis
(x1000)		 Unrealized
Gain/Loss
(x1000)
2026-04-29 2026-03-31 13F CYTOKINETICS COM NEW 23282W605 483,274 213 0.04 31,853 3.78 0.0279
2026-01-16 2025-12-31 13F CYTOKINETICS COM NEW 23282W605 483,061 -444,771 -47.94 30,694 -39.81 0.0475
2025-11-07 2025-09-30 13F CYTOKINETICS COM NEW 23282W605 927,832 4,903 0.53 50,994 67.23 0.0807
2025-07-24 2025-06-30 13F CYTOKINETICS COM NEW 23282W605 922,929 320,508 53.20 30,494 25.95 0.0519
2025-05-13 2025-03-31 13F CYTOKINETICS COM NEW 23282W605 602,421 151,908 33.72 24,211 14.25 0.0472
2025-01-24 2024-12-31 13F CYTOKINETICS COM NEW 23282W605 450,513 102,457 29.44 21,192 15.32 0.0398
2024-10-25 2024-09-30 13F CYTOKINETICS COM NEW 23282W605 348,056 -21,181 -5.74 18,377 -8.14 0.0337
2024-08-09 2024-06-30 13F CYTOKINETICS COM NEW 23282W605 369,237 129,995 54.34 20,005 19.27 0.0383
2024-05-09 2024-03-31 13F CYTOKINETICS COM NEW 23282W605 239,242 108,982 83.66 16,773 54.23 0.0329
2024-01-31 2023-12-31 13F CYTOKINETICS COM NEW 23282W605 130,260 130,260 10,875 0.0236
Legend
Shares
The total number of shares held by the institution at the end of the reporting period (the effective date). This is provided in the filing.
Value
The total value of the shares as of the effective date. This is provided in the filing.
Avg. Share Price
The weighted average share price of the shares held by the institution. We use FIFO accounting to determine this price
Class
This is the security class as indicated by the filer. There are a variety of values for this field. Common values include "EC" = equity common, "EP" - equity preferred
Allocation (%)
The percent of the institution's portfolio that this position represents. This is provided in NPORT filings. For 13F filings, we calculate it.
Change in Allocation
The change in allocation from the prior reporting period. This is calculated as current allocation - prior allocation.
Change in Allocation (%)
The percent change in allocation from the prior reporting period. This is calculated as (current allocation - prior allocation) / prior allocation.
Cost Basis
The total cost of the shares held. This is calculated as reported shares * avg. share price
Unrealized Gain/Loss
This is the market value of the position as of the effective date minus the cost basis.